Timothy E. Morey

Corporate Officer/Principal at University of Florida

Health Technology

Consumer Services

Profile

Dr. Timothy E.
Morey, MD, is a Professor at University of Florida and a Principal at Kegonsa Capital Partners LLC.
He is on the Board of Directors at Nanomedex Pharmaceuticals, Inc. He received his doctorate degree from the University of Florida.

Timothy E. Morey active positions

Companies	Position	Start
University of Florida	Corporate Officer/Principal	25/11/2009

All active positions of Timothy E. Morey

Former positions of Timothy E. Morey

Companies	Position	End
NanoMedex Pharmaceuticals, Inc. NanoMedex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NanoMedex Pharmaceuticals, Inc. develops formulation strategy to allow drugs that are only soluble in oil to be soluble in water. It offers offers Microfol, a micro emulsion formulation containing the generic active pharmaceutical ingredient propofol and two IIG listed excipients-sodium caprylate and poloxamer, which replaces the macro emulsion components of the reference listed drug and its generic equivalents. The company’s formulation is applied to drug classes, including chemotherapeutics, anesthetics, anti-infective, anti-inflammatories and arrythmics, immunosuppressants, and vitamins. NanoMedex Pharmaceuticals was founded by Donn M. Dennis, Nikolaus Gravenstein, Jerome H. Modell and Timothy E. Morey in 2002 and is headquartered in Middleton, WI.	Founder	-

See the detail of Timothy E. Morey's experience

Training of Timothy E. Morey

University of Florida

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Timothy E. Morey's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
NanoMedex Pharmaceuticals, Inc. NanoMedex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NanoMedex Pharmaceuticals, Inc. develops formulation strategy to allow drugs that are only soluble in oil to be soluble in water. It offers offers Microfol, a micro emulsion formulation containing the generic active pharmaceutical ingredient propofol and two IIG listed excipients-sodium caprylate and poloxamer, which replaces the macro emulsion components of the reference listed drug and its generic equivalents. The company’s formulation is applied to drug classes, including chemotherapeutics, anesthetics, anti-infective, anti-inflammatories and arrythmics, immunosuppressants, and vitamins. NanoMedex Pharmaceuticals was founded by Donn M. Dennis, Nikolaus Gravenstein, Jerome H. Modell and Timothy E. Morey in 2002 and is headquartered in Middleton, WI.	Health Technology